A previous meta-analysis also demonstrated that NSCLC patients harboring a deletion polymorphism in the Bim gene exhibited a diminished response to EGFR-TKIs [29] indicating that Bim may be essential for deriving therapeutic benefits from afatinib treatment in HNC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.